Insulet Corporation is trading at $153.00 (down 4.1%), giving back part of its sharp June 9, 2026, jump that followed optimism around Omnipod 5 software upgrades and expanded CGM compatibility.
- The stock's pullback is largely attributed to profit-taking as investors lock in gains from the recent product-news rally.
- Shares are also facing pressure from broad market weakness, with major U.S. indices down over 1% in a shift toward risk-off sentiment across equities.